Literature DB >> 23809711

Herpes zoster.

Kim M O'Connor1, Douglas S Paauw.   

Abstract

Herpes zoster is a common condition that significantly affects health-related quality of life. Most cases occur in immunocompetent individuals older than 60 years; however, immunosuppressed patients are at particularly high risk. Post-herpetic neuralgia is the most common serious complication of herpes zoster, and is much more common in the very elderly. Vaccination with the zoster vaccine is recommended for most people older than 60, and reduces the incidence of herpes zoster and the occurrence of post-herpetic neuralgia.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23809711     DOI: 10.1016/j.mcna.2013.02.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  17 in total

Review 1.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

Review 2.  Gaps in Aging Research as it Applies to Rheumatologic Clinical Care.

Authors:  Una E Makris; Devyani Misra; Raymond Yung
Journal:  Clin Geriatr Med       Date:  2016-10-18       Impact factor: 3.076

3.  Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.

Authors:  Chris P Verschoor; Alina Lelic; Robin Parsons; Carole Evelegh; Jonathan L Bramson; Jennie Johnstone; Mark B Loeb; Dawn M E Bowdish
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

4.  Neuroimmune-Glia Interactions in the Sensory Ganglia Account for the Development of Acute Herpetic Neuralgia.

Authors:  Jaqueline R Silva; Alexandre H Lopes; Jhimmy Talbot; Nerry T Cecilio; Mateus F Rossato; Rangel L Silva; Guilherme R Souza; Cassia R Silva; Guilherme Lucas; Benedito A Fonseca; Eurico Arruda; Jose C Alves-Filho; Fernando Q Cunha; Thiago M Cunha
Journal:  J Neurosci       Date:  2017-06-02       Impact factor: 6.167

5.  Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.

Authors:  Naum Shaparin; Patricia W Slattum; Iwona Bucior; Srinivas Nalamachu
Journal:  Clin J Pain       Date:  2015-11       Impact factor: 3.442

6.  Edema Bullae Mimicking Disseminated Herpes Zoster.

Authors:  Stella X Chen; Philip R Cohen
Journal:  Cureus       Date:  2017-10-17

7.  The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks.

Authors:  La'Marcus T Wingate; Keisha Stubbs; Iman Ahmed; Rachel K Mayaka; Mary K Maneno; Earl Ettienne; Oluchi Elekwachi; Veronica Clarke-Tasker
Journal:  Int J Environ Res Public Health       Date:  2018-09-27       Impact factor: 3.390

8.  Transcriptome Analysis Reveals the Role of Cellular Calcium Disorder in Varicella Zoster Virus-Induced Post-Herpetic Neuralgia.

Authors:  Songbin Wu; Shaomin Yang; Mingxi Ou; Jiamin Chen; Jiabing Huang; Donglin Xiong; Wuping Sun; Lizu Xiao
Journal:  Front Mol Neurosci       Date:  2021-05-17       Impact factor: 5.639

Review 9.  Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects.

Authors:  Gisèle Pickering
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 4.271

10.  Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.

Authors:  Michel Fochesato; Najoua Dendouga; Mathieu Boxus
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.